Human TIM-3 Antibody | R&D Systems AF2365 product information

product summary

company name :

R&D Systems

product type :

antibody

product name :

Human TIM-3 Antibody

catalog :

AF2365

quantity :

100 ug (also 25 ug)

price :

489 USD

clonality :

polyclonal

host :

domestic goat

conjugate :

nonconjugated

reactivity :

human

application :

western blot, immunohistochemistry, immunocytochemistry, neutralization, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section

more info or order :

R&D Systems product webpage

citations: 23

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry - paraffin section; human; 1:400; loading ...; fig 4e	Ebata N, Fujita M, Sasagawa S, Maejima K, Okawa Y, Hatanaka Y, et al. Molecular Classification and Tumor Microenvironment Characterization of Gallbladder Cancer by Comprehensive Genomic and Transcriptomic Analysis. Cancers (Basel). 2021;13: pubmed publisher
western blot; human; loading ...; fig 6a	Wang J, Qiao L, Hou Z, Luo G. TIM-1 Promotes Hepatitis C Virus Cell Attachment and Infection. J Virol. 2017;91: pubmed publisher
	Koh J, Lee D, Kim S, Song S, Han B, Jeong H, et al. Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression. Cancer Immunol Res. 2024;12:1753-1764 pubmed publisher
	Chongsaritsinsuk J, Steigmeyer A, Mahoney K, Rosenfeld M, Lucas T, Smith C, et al. Glycoproteomic landscape and structural dynamics of TIM family immune checkpoints enabled by mucinase SmE. Nat Commun. 2023;14:6169 pubmed publisher
	Saliby R, El Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, et al. Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma. Cancer Immunol Res. 2023;11:1114-1124 pubmed publisher
	Calvet Mirabent M, S xe1 nchez Cerrillo I, Mart xed n C xf3 freces N, Mart xed nez Fleta P, de la Fuente H, Tsukalov I, et al. Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV. EBioMedicine. 2022;81:104090 pubmed publisher
	Bakouny Z, Sadagopan A, Ravi P, Metaferia N, Li J, Abuhammad S, et al. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 2022;38:110190 pubmed publisher
	Smith C, Li A, Krishnamurthy N, Lemmon M. Phosphatidylserine binding directly regulates TIM-3 function. Biochem J. 2021;478:3331-3349 pubmed publisher
	Sarradin V, Lusque A, Filleron T, Dalenc F, Franchet C. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study. Breast Cancer Res. 2021;23:61 pubmed publisher
	Zhong W, Liu X, Zhu Z, Li Q, Li K. High levels of Tim-3+Foxp3+Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large B cell lymphoma patients. Int Immunopharmacol. 2021;96:107662 pubmed publisher
	Braun D, Street K, Burke K, Cookmeyer D, Denize T, Pedersen C, et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021;39:632-648.e8 pubmed publisher
	Martinez M, Kim S, St Jean N, O Brien S, Lian L, Sun J, et al. Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer. Oncoimmunology. 2021;10:1873607 pubmed publisher
	Chevrier S, Zurbuchen Y, Cervia C, Adamo S, Raeber M, de Souza N, et al. A distinct innate immune signature marks progression from mild to severe COVID-19. Cell Rep Med. 2021;2:100166 pubmed publisher
	Li H, Wang J, Liu H, Lan T, Xu L, Wang G, et al. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma. Aging (Albany NY). 2020;12:3451-3472 pubmed publisher
	Li W, Han J, Yuan K, Wu H. Integrated tumor stromal features of hepatocellular carcinoma reveals two distinct subtypes with prognostic/predictive significance. Aging (Albany NY). 2019;11:4478-4509 pubmed publisher
	Gordian E, Welsh E, Gimbrone N, Siegel E, Shibata D, Creelan B, et al. Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. Oncotarget. 2019;10:810-824 pubmed publisher
	Franchini D, Lanvin O, Tosolini M, Patras de Campaigno E, Cammas A, Péricart S, et al. Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells. Cell Rep. 2019;26:94-107.e7 pubmed publisher
	Zhao D, Guo M, Liu B, Lin Q, Xie T, Zhang Q, et al. Frontline Science: Tim-3-mediated dysfunctional engulfment of apoptotic cells in SLE. J Leukoc Biol. 2017;102:1313-1322 pubmed publisher
	Zhao J, Shiratori B, Chagan Yasutan H, Matsumoto M, Niki T, Tanaka M, et al. Secretion of IFN-Î³ Associated with Galectin-9 Production by Pleural Fluid Cells from a Patient with Extrapulmonary Tuberculosis. Int J Mol Sci. 2017;18: pubmed publisher
	Mohammed T, Chagan Yasutan H, Ashino Y, Nakayama W, Takahashi Y, Shimomura T, et al. Galectin-9 as a Predictive Marker for the Onset of Immune-Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell Leukemia. Tohoku J Exp Med. 2017;241:201-208 pubmed publisher
	Schwartz J, Clayton K, Mujib S, Zhang H, Rahman A, Liu J, et al. Tim-3 is a Marker of Plasmacytoid Dendritic Cell Dysfunction during HIV Infection and Is Associated with the Recruitment of IRF7 and p85 into Lysosomes and with the Submembrane Displacement of TLR9. J Immunol. 2017;198:3181-3194 pubmed publisher
	Li B, Severson E, Pignon J, Zhao H, Li T, Novak J, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17:174 pubmed publisher
	Clayton K, Douglas Vail M, Nur Ur Rahman A, Medcalf K, Xie I, Chew G, et al. Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression. J Virol. 2015;89:3723-36 pubmed publisher

product information

master code :

AF2365

SKU :

AF2365

product name :

Human TIM-3 Antibody

unit size :

100 ug (also 25 ug)

description :

The Human TIM-3 Antibody from R&D Systems is a goat polyclonal antibody to TIM-3. This antibody reacts with human. The Human TIM-3 Antibody has been validated for the following applications: Immunohistochemistry,Neutralization,Flow Cytometry,Immunoprecipitation,Western Blot,Immunohistochemistry-Paraffin,Immunocytochemistry,CyTOF-ready,Knockout Validated,Dual RNAscope ISH-IHC Compatible.

target :

TIM-3

category :

Primary Antibodies

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 ╡m filtered solution in PBS.

clonality :

Polyclonal

concentration :

LYOPH

conjugate :

Unconjugated

host :

Goat

immunogen :

Mouse myeloma cell line NS0-derived recombinant human TIM-3, Ser22-Arg200, Accession # Q8TDQ0

isotype :

IgG

purity :

Antigen Affinity-purified

species :

Human

specificity :

Detects human TIM-3 in direct ELISAs and Western blots. In direct ELISAs, approximately 5% cross-reactivity with recombinant mouse (rm) TIM-3 is observed and less than 1% cross-reactivity with recombinant human TIM-1, rmTIM-1, and rmTIM-2 is observed.

gene symbol :

HAVCR2

Antibody validation :

Knockout/Knockdown

top caption :

TIM-3 antibody in Human Tonsil Using Dual RNAscope«ISH and IHC.

accessionNumbers :

Q8TDQ0

applications :

Immunohistochemistry,Flow Cytometry,Immunoprecipitation,Western Blot,Neutralization,Immunohistochemistry-Paraffin,Immunocytochemistry,CyTOF-ready,Knockout Validated,Dual RNAscope ISH-IHC Compatible

USD :

489 USD

alt names :

CD366, FLJ14428, HAVcr-2, HAVCR2, hepatitis A virus cellular receptor 2, kidney injury molecule-3, KIM-3, SPTCL, T cell immunoglobulin mucin 3, T cell immunoglobulin mucin-3, T-cell immunoglobulin and mucin domain-containing protein 3, TIM 3, Tim-3, TIM3, TIM3 T-cell membrane protein 3, TIMD3, TIMD-3, TIMD3KIM-3

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 6 months, -20 to -70 ░C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage